Latest news
Real-World Analysis Explores GLP-1 Use and Overall Survival - Targeted OncologyTargeted Oncology · Tue, 04 Aug 2026 22:08:47 GMTAstraZeneca's Claudin 18.2-targeting ADC passes pivotal gastric cancer test - FirstWord PharmaFirstWord Pharma · Mon, 27 Jul 2026 20:25:00 GMTDabrafenib Plus Trametinib Improves Progression-Free Survival in BRAF V600E-Positive Differentiated Thyroid Cancer - The ASCO PostThe ASCO Post · Mon, 27 Jul 2026 14:48:53 GMTSonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers - AstraZenecaAstraZeneca · Mon, 27 Jul 2026 07:00:00 GMT